World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
46
Citations
9514
World Ranking
15898
National Ranking
3976

Overview

Frederick Cohen is affiliated with Nurix Therapeutics in the United States. Their research predominantly spans the fields of Medicine and Immunology and Microbiology, with focused work in several subfields including Oncology, Immunology, Molecular Biology, Genetics, and Public Health, Environmental and Occupational Health.

The primary areas of study for Frederick Cohen include CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors, Cancer Immunotherapy and Biomarkers, Ubiquitin and proteasome pathways, Immunotherapy and Immune Responses, and Acute Lymphoblastic Leukemia research.

Frederick Cohen has contributed to the scientific community with numerous publications, mainly focused on cancer immunotherapy, small molecule inhibitors, and protein degradation modalities. Notable recent papers include:

  • Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies (2024, Journal of Medicinal Chemistry)
  • Abstract 1595: Small molecule inhibition of the ubiquitin ligase CBL-B results in potent T and NK cell mediated anti-tumor response (2021, Cancer Research)
  • 98 NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy (2021, Regular and Young Investigator Award Abstracts)
  • 331 A novel small molecule inhibitor of CBL-B shows potent antitumor activity in combination with Pmel-1 adoptive cell transfer in an aggressive mouse melanoma model (2022, Regular and Young Investigator Award Abstracts)
  • Abstract 7003: NX-5948 is a CNS-penetrant catalytic Bruton's tyrosine kinase (BTK) degrader that breaks established design rules for CNS drugs (2025, Cancer Research)

Frequent coauthors with whom Frederick Cohen has collaborated include:

  • Gwenn M. Hansen
  • Ryan B. Rountree
  • Austin Tenn-McClellan
  • Arthur Sands
  • Cristiana Guiducci

Frederick Cohen's work has been published in several recurring scientific venues, particularly:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Journal of Medicinal Chemistry

Best Publications

  • Pathway complexity of prion protein assembly into amyloid.

    Ilia V. Baskakov;Giuseppe Legname;Michael A. Baldwin;Stanley B. Prusiner

  • Structural studies of the scrapie prion protein by electron crystallography

    Holger Wille;Melissa D. Michelitsch;Vincent Guénebaut;Surachai Supattapone

  • Identification of the Cu2+ Binding Sites in the N-Terminal Domain of the Prion Protein by EPR and CD Spectroscopy

    Eliah Aronoff-Spencer;Colin S. Burns;Nikolai I. Avdievich;Gary J. Gerfen

  • Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid.

    Maria Gasset;Michael A. Baldwin;David H. Lloyd;Jean-Marc Gabriel

  • Elimination of prions by branched polyamines and implications for therapeutics

    Surachai Supattapone;Hoang-Oanh B. Nguyen;Fred E. Cohen;Stanley B. Prusiner

  • Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target

    Shiming Ye;Yadong Huang;Karin Müllendorff;Liming Dong

  • COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform

    Kiyotoshi Kaneko;Martin Vey;Michael Scott;Susanne Pilkuhn

  • USP7 small-molecule inhibitors interfere with ubiquitin binding

    Lorna Kategaya;Paola Di Lello;Lionel Rougé;Richard Pastor

  • Prion protein peptides induce alpha-helix to beta-sheet conformational transitions.

    Jack Nguyen;Michael A. Baldwin;Fred E. Cohen;Stanley B. Prusiner

  • A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery

    John E. Murphy;Tetsuo Uno;Janice D. Hamer;Fred E. Cohen

  • Branched Polyamines Cure Prion-Infected Neuroblastoma Cells

    Surachai Supattapone;Holger Wille;Lisa Uyechi;Jiri Safar

  • Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152).

    John A. Flygare;Maureen Beresini;Nageshwar Budha;Helen Chan

  • Recombinant scrapie-like prion protein of 106 amino acids is soluble

    Tamaki Muramoto;Michael Scott;Fred E. Cohen;Stanley B. Prusiner

  • Natural and synthetic prion structure from X-ray fiber diffraction

    Holger Wille;Wen Bian;Michele McDonald;Amy Kendall

  • Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes.

    Giuseppe Legname;Hoang-Oanh B. Nguyen;David Peretz;Fred E. Cohen

  • Proposed three-dimensional structure for the cellular prion protein

    Ziwei Huang;Jean-Marc Gabriel;Michael A. Baldwin;Robert J. Fletterick

  • Evolutionarily conserved Galphabetagamma binding surfaces support a model of the G protein-receptor complex.

    Olivier Lichtarge;Henry R. Bourne;Fred E. Cohen

  • Doppel Is an N-Glycosylated, Glycosylphosphatidylinositol-anchored Protein EXPRESSION IN TESTIS AND ECTOPIC PRODUCTION IN THE BRAINS OFPrnp 0/0 MICE PREDISPOSED TO PURKINJE CELL LOSS

    Gregory L. Silverman;Kefeng Qin;Richard C. Moore;Ying Yang

  • Potent inhibition of scrapie prion replication in cultured cells by bis-acridines

    Barnaby C. H. May;Aaron T. Fafarman;Septima B. Hong;Michael Rogers

  • Structure−Activity Relationship Study of Prion Inhibition by 2-Aminopyridine-3,5-dicarbonitrile-Based Compounds: Parallel Synthesis, Bioactivity, and in Vitro Pharmacokinetics.

    Barnaby C. H. May;Julie A. Zorn;Juanita Witkop;John Sherrill

Frequent Co-Authors

Stanley B. Prusiner
Stanley B. Prusiner University of California, San Francisco
Larry E. Overman
Larry E. Overman University of California, Irvine
Michael A. Baldwin
Michael A. Baldwin University of California, San Francisco
Stephen J. DeArmond
Stephen J. DeArmond University of California, San Francisco
Holger Wille
Holger Wille University of Alberta
Giuseppe Legname
Giuseppe Legname International School for Advanced Studies
Michelle R. Arkin
Michelle R. Arkin University of California, San Francisco
Domagoj Vucic
Domagoj Vucic Genentech

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Chemistry in the USA opens doors to a variety of career paths that extend beyond the traditional lab roles. With the rise of online education, several related fields offer flexible degree options to enhance your skills and job prospects.

For those interested in legal aspects of chemistry, pursuing a paralegal degree can prepare you to support intellectual property cases involving chemical patents or environmental law.

Another promising avenue is the pharmaceutical industry. Understanding chemistry fundamentals can help you transition into roles such as a drug sales representative. To explore potential earnings and career paths, check out detailed insights on how much do drug reps make.

If you're drawn to advanced clinical roles, becoming a pharmacist is a natural step. Chemistry knowledge is key to this demanding career, with clear guidance available on how to become a pharmacist salary and certification paths.

For students fascinated by forensic applications, training as an autopsy technician combines biology and chemistry. Learn more about the educational requirements and job outlook when you explore how to become an autopsy technician.

By leveraging related online degrees and career insights, Chemistry graduates can expand their expertise and secure meaningful, high-demand positions across diverse industries.

Best Scientists Citing Frederick Cohen

Trending Scientists

Recently Published Articles